RxDoctor Payments Data

Hal Hooper, MD

Urology · Asheville, NCNPI 1497906424

Payments from drug & device makers

$5,073in general payments, 2019–2025

Across 244 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$629
  • Angiodynamics, Inc.$531
  • Pfizer$478
  • Johnson & Johnson$472
  • AbbVie$455
  • Astellas Pharma US Inc$411
  • plus $2K from 36 others

What the payments were for

  • Travel & lodging$50110%
  • Food & beverage$4,42687%
  • Education$1473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,073 in reported general payments places this provider in the 65th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$255,794
Medicare patients
643
Services billed
8,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron130$114,953
OrgovyxRelugolix19$48,259
MyrbetriqMirabegron62$44,329
ElmironPentosan Polysulfate Sodium13$11,644
Tamsulosin Hcl638$8,611
Potassium Citrate ErPotassium Citrate79$6,892
Estradiol40$2,605
Alfuzosin Hcl ErAlfuzosin Hcl99$1,633
Finasteride106$1,416
Testosterone Cypionate21$1,272
Oxybutynin Chloride66$1,162
Tadalafil12$1,114
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$1,038
Cephalexin89$920
Ciprofloxacin Hcl124$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$164$163,212149 claims
Astellas Pharma US IncMyrbetriq$411$44,32962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 434 urology providers in North Carolina.

Other urology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →